医学
骨髓增生异常综合症
来那度胺
危险分层
内科学
肿瘤科
贫血
国际预后积分系统
临床试验
重症监护医学
多发性骨髓瘤
骨髓
作者
Talha Badar,Yazan F. Madanat,Amer M. Zeidan
出处
期刊:Future Oncology
[Future Medicine]
日期:2023-09-01
卷期号:19 (27): 1877-1889
标识
DOI:10.2217/fon-2023-0454
摘要
The majority of lower-risk myelodysplastic syndromes/neoplasms patients present with anemia. Historically, these patients were treated with erythropoiesis-stimulating agents (ESA), with modest responses. A subset of these patients with del(5q) may do better with lenalidomide. Recently, in randomized trials, luspatercept has shown better responses compared with ESAs in treatment-naive patients and imetelstat in patients refractory to ESAs. Other evaluated novel compounds (fostamatinib, H3B-880, roxadustat, pyruvate kinase receptor activator) have not yet shown meaningful efficacy. More needs to be done to improve outcomes; in pursuance of this, participation in clinical trials evaluating novel therapies should be encouraged. While lower-risk myelodysplastic syndromes/neoplasms tend to have an indolent course, a subset of them has a dismal prognosis. Improving prognostication and serial monitoring will help in identifying high-risk patients for appropriate management.
科研通智能强力驱动
Strongly Powered by AbleSci AI